Genetic markers of oxidative stress and coronary atherosclerosis

Current Atherosclerosis Reports

Volumn 8, Issue 3, 2006, Pages 177-183

  Madamanchi, Nageswara R ^b   Tchivilev, Igor ^b   Runge, Marschall S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE REDUCTASE; HEME OXYGENASE; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ACUTE CORONARY SYNDROME; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENVIRONMENTAL FACTOR; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEREDITY; HOMEOSTASIS; HUMAN; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HEME OXYGENASE (DECYCLIZING); HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES;

EID: 33646388271     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0071-3     Document Type: Review

References (50)

1. Madamanchi NR, Moon SK, Hakim ZS, et al.: Differential activation of mitogenic signaling pathways in aortic smooth muscle cells deficient in superoxide dismutase isoforms. Arterioscler Thromb Vasc Biol 2005, 25:950-956.
2. Liu H, Colavitti R, Rovira II, et al.: Redox dependent transcriptional regulation. Circ Res 2005, 97:967-974.
3. Marenberg ME, Risch N, Berkman LF, et al.: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994, 330:1041-1046.
4. Lusis AJ, Fogelman AM, Fonarow GC: Genetic basis of atherosclerotis: part I: new genes and pathways. Circulation 2004, 110:1868-1873.
5. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29-38.
6. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912-1916.
7. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
8. Sorescu D, Weiss D, Lassegue B, et al.: Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105:1429-1435.
9. Patterson C, Ruef J, Madamanchi NR, et al.: Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999, 274:19814-19822.
10. Soccio M, Toniato E, Evangelista V, et al.: Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. Eur J Clin Invest 2005, 35:305-314.
11. Laude K, Cai H, Fink B, et al.: Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. Am J Physiol Heart Circ Physiol 2005, 288:H7-H12.
12. Mollnau H, Wendt M, Szocs K, et al.: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002, 90:E58-E65.
13. Dinauer MC, Pierce EA, Bruns GA, et al.: Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 1990, 86:1729-1737.
14. Inoue N, Kawashima S, Kanazawa K, et al.: Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998, 97:135-137.
15. Wyche KE, Wang SS, Griendling KK, et al.: C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 2004, 43:1246-1251.
16. Guzik TJ, West NE, Black E, et al.: Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000, 102:1744-1747.
17. Schachinger V, Britten MB, Dimmeler S, et al.: NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur Heart J 2001, 22:96-101.
18. Schneider MP, Hilgers KF, Huang Y, et al.: The C242T p22phox polymorphism and endothelium-dependent vasodilation in subjects with hypercholesterolaemia. Clin Sci (Lond) 2003, 105:97-103.
19. Hayaishi-Okano R, Yamasaki Y, Ohtoshi K, et al.: NAD (P) H oxidase p22 phox C242T polymorphism affects LDL particle size and insulin resistance in Japanese subjects. J Atheroscler Thromb 2002, 9:200-205.
20. Gardemann A, Mages P, Katz N, et al.: The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 1999, 145:315-323.
21. Li A, Prasad A, Mincemoyer R, et al.: Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet 1999, 86:57-61.
22. Marsden PA, Heng HH, Scherer SW, et al.: Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993, 268:17478-17488.
23. Cattaruzza M, Guzik TJ, Slodowski W, et al.: Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res 2004, 95:841-847.
24. Voetsch B, Loscalzo J: Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 2004, 24:216-229.
25. Stangl K, Cascorbi I, Laule M, et al.: High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 2000, 10:133-140.
26. Yoshimura M, Yasue H, Nakayama M, et al.: A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998, 103:65-69.
27. Persu A, Stoenoiu MS, Messiaen T, et al.: Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002, 11:229-241.
28. Casas JP, Hingorani AD, Humphries SE, et al.: Do meta-analyses of association studies of endothelial nitric oxide synthase variants and ischemic heart disease provide conclusive answers? Circulation 2004, 110:e305-e306.
29. Casas JP, Bautista LE, Humphries SE, et al.: Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004, 109:1359-1365.
30. Daugherty A, Dunn JL, Rateri DL, et al.: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437-444.
31. Piedrafita FJ, Molander RB, Vansant G, et al.: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996, 271:14412-14420.
32. Nikpoor B, Turecki G, Fournier C, et al.: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001, 142:336-339.
33. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, et al.: Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004, 116:429-430.
34. Balaban RS, Nemoto S, Finkel T: Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
35. Takagi K, Yamada Y, Gong JS, et al.: Association of a 5178C→A (Leu237Met) polymorphism in the mitochondrial DNA with a low prevalence of myocardial infarction in Japanese individuals. Atherosclerosis 2004, 175:281-286.
36. Kokaze A, Ishikawa M, Matsunaga N, et al.: Association of the mitochondrial DNA 5178 A/C polymorphism with serum lipid levels in the Japanese population. Hum Genet 2001, 109:521-525.
37. Dhamrait SS, Stephens JW, Cooper JA, et al.: Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J 2004, 25:468-475.
38. Rosenblat M, Karry R, Aviram M: Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2005, In press.
39. Clendenning JB, Humbert R, Green ED, et al.: Structural organization of the human PON1 gene. Genomics 1996, 35:586-589.
40. Leviev I, Righetti A, James RW: Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 2001, 79:457-463.
41. Leviev I, Poirier O, Nicaud V, et al.: High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 2002, 161:463-467.
42. Garin MC, James RW, Dussoix P, et al.: Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997, 99:62-66.
43. Imai Y, Morita H, Kurihara H, et al.: Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000, 149:435-442.
44. Wheeler JG, Keavney BD, Watkins H, et al.: Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004, 63:689-695.
45. Blankenberg S, Rupprecht HJ, Bickel C, et al.: Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003, 349:1605-1613.
46. Lapenna D, de Gioia S, Ciofani G, et al.: Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 1998, 97:1930-1934.
47. Winter JP, Gong Y, Grant PJ, et al.: Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron Artery Dis 2003, 14:149-153.
48. Kaneda H, Ohno M, Taguchi J, et al.: Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002, 22:1680-1685.
49. Chen YH, Lin SJ, Lin MW, et al.: Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002, 111:1-8.
50. Novotny L, Vitek L: Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003, 228:568-571.